Perinatal Identification, Referral and Integrated Management for Improving Depression: The PIRIMID Study

Not Applicable

• Conditions: Postnatal depression; Postnatal anxiety; Mental Health - Depression; Reproductive Health and Childbirth - Childbirth and postnatal care; Mental Health - Anxiety

• Registration Number: ACTRN12619001433190
• Lead Sponsor: Professor Jeannette Milgrom

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-10-16
• Last Update Posted: 22 October 2019

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Female
• Target Recruitment: 1650

Inclusion Criteria

Ability to understand spoken and written English language
Baby aged 6-10 weeks

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Treatment uptake. Proportion of women who have received help for their mental heath from GP, psychologist or psychiatrist as measured by questionnaire. This question is designed specifically for this study. [baseline, 4 and 6 (primary endpoint) months postnatal];Acceptability and Satisfaction of experience with PIRIMID or current best-practice for women and nurses as measured by 10 point Likert-type scale, [8-week KAS visit]

Secondary Outcome Measures

Name	Time	Method
ptake of secondary services and other sources of help and social support accessed. As measured by questionnaires. This questionnaire is designed specifically for this study.[Baseline (8-week KAS visit), 4 and 6 months postnatal];Anxiety and Stress symptoms as measured by the Depression, Anxiety and Stress Scales (DASS-21)[4 and 6 months postnatal];Health Economic Measures. <br>Health-related Quality of life - measured by EQoL-5D-5L, <br>Productivity costs - measured by iMTA Productivity Cost Questionnaire: iPCQ, <br>Health care costs - estimated based on health care resource utilization obtained from patient-reported resource/service use and Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Scheme (PBS).[Baseline (8-week KAS visit), 4 and 6 months postnatal]